Takuma Yokoyama

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)

Nobuyuki Katakami, Junji Uchino, Takuma Yokoyama et al. · Cancer · 2017 · 243 citations · Full text

Medicine, Oncology, Pharmacology +16

Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial

Koichi Takayama, Nobuyuki Katakami, Takuma Yokoyama et al. · Supportive Care in Cancer · 2016 · 142 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients—Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study

Koichi Takayama, Shinji Atagi, Fumio Imamura et al. · Supportive Care in Cancer · 2016 · 98 citations · Full text

Medicine, Oncology, Cancer Control +16

Kinetics of c-reactive protein (CRP) and serum amyloid A protein (SAA) in patients with community-acquired pneumonia (CAP), as presented with biologic half-life times

Saori Takata, Hiroo Wada, Masaki Tamura et al. · Biomarkers · 2011 · 52 citations

Veterinary Medicine, Clinical Sciences, Infectious Diseases +16